LLY

920.2

+0.28%↑

JNJ

235.65

-0.72%↓

ABBV

206.42

-0.47%↓

NVS

146.45

-1.15%↓

AZN

185.48

-1.36%↓

LLY

920.2

+0.28%↑

JNJ

235.65

-0.72%↓

ABBV

206.42

-0.47%↓

NVS

146.45

-1.15%↓

AZN

185.48

-1.36%↓

LLY

920.2

+0.28%↑

JNJ

235.65

-0.72%↓

ABBV

206.42

-0.47%↓

NVS

146.45

-1.15%↓

AZN

185.48

-1.36%↓

LLY

920.2

+0.28%↑

JNJ

235.65

-0.72%↓

ABBV

206.42

-0.47%↓

NVS

146.45

-1.15%↓

AZN

185.48

-1.36%↓

LLY

920.2

+0.28%↑

JNJ

235.65

-0.72%↓

ABBV

206.42

-0.47%↓

NVS

146.45

-1.15%↓

AZN

185.48

-1.36%↓

Search

Ionis Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

71.28 0.68

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

70.53

Max

72.48

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+33.31% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.8B

12B

Ankstesnė atidarymo kaina

70.6

Ankstesnė uždarymo kaina

71.28

Naujienos nuotaikos

By Acuity

50%

50%

155 / 350 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-19 18:34; UTC

Uždarbis

Canada to Allow Smaller Companies to Ax Quarterly Earnings Reports in Pilot

2026-03-19 17:43; UTC

Pagrindinės rinkos jėgos

Ecolab Dips on Report of Deal for CoolIT Systems With KKR

2026-03-19 23:47; UTC

Uždarbis

COSCO SHIPPING Holdings: Geopolitical Tensions Will Continue Driving Regional Fragmentation >1919.HK

2026-03-19 23:47; UTC

Uždarbis

COSCO SHIPPING Holdings: Container Shipping Market Saw Fluctuating, Declining Freight Rates >1919.HK

2026-03-19 23:47; UTC

Uždarbis

COSCO SHIPPING Holdings 2025 Rev CNY219.50B Vs. CNY233.86B >1919.HK

2026-03-19 23:47; UTC

Uždarbis

COSCO SHIPPING Holdings 2025 Net CNY30.86B Vs. Net CNY49.17B >1919.HK

2026-03-19 23:39; UTC

Uždarbis

Li Ning 2025 Net CNY2.94B Vs. Net CNY3.01B >2331.HK

2026-03-19 23:39; UTC

Uždarbis

Li Ning: Will Continue Targeting Consumer Needs, Strengthening User Engagement >2331.HK

2026-03-19 23:39; UTC

Uždarbis

Li Ning: Outdoor Category Continued Growing >2331.HK

2026-03-19 23:38; UTC

Uždarbis

Li Ning 2025 Rev CNY29.60B Vs. CNY28.68B >2331.HK

2026-03-19 23:33; UTC

Rinkos pokalbiai

Gold Edges Lower on Inflation Concerns, Dimmed Fed Rate-Cut Hopes -- Market Talk

2026-03-19 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Unilever in Talks to Separate Food Business and Combine It With McCormick -- WSJ

2026-03-19 22:42; UTC

Įsigijimai, susijungimai, perėmimai

McCormick Has a Market Value of Around $14.8B -- WSJ

2026-03-19 22:42; UTC

Įsigijimai, susijungimai, perėmimai

Unilever in Talks to Combine Food Business With McCormick, Sources Say -- WSJ

2026-03-19 22:42; UTC

Įsigijimai, susijungimai, perėmimai

All-Stock Unilever-McCormick Deal Could Come Together Within Weeks, Sources Say -- WSJ

2026-03-19 22:23; UTC

Rinkos pokalbiai

FedEx Says It Can Raise Prices to Offset Higher Fuel Costs -- Market Talk

2026-03-19 22:09; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Australian Transport Stocks to Trade at Discount On Fuel Risks -- Market Talk

2026-03-19 22:06; UTC

Rinkos pokalbiai

Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk

2026-03-19 22:04; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

FedEx CFO: MD-11 Grounding Led to $120M Headwind to Adjusted Operating Income in 3Q

2026-03-19 22:03; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Global Energy Roundup: Market Talk

2026-03-19 22:03; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Fuel Prices, Scarcity Could Leave Mark on Australia's Gold Miners -- Market Talk

2026-03-19 21:51; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

FedEx CEO: InPost Deal Expected to Be Accretive to Earnings in Year One After Close

2026-03-19 20:57; UTC

Svarbiausios naujienos

Middle East Attacks, Inflation Fears Weigh on Stocks -- WSJ

2026-03-19 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-19 20:19; UTC

Svarbiausios naujienos

Brent Crude Retreats After Touching $119 -- WSJ

2026-03-19 19:49; UTC

Rinkos pokalbiai

Brent Crude Seen Potentially Rising to Top Its 2008 High -- Market Talk

2026-03-19 19:26; UTC

Svarbiausios naujienos

U.S. Consumers Face 'Global Oil Shock.' The Iran War Is Retail's Latest Challenge. -- Barrons.com

2026-03-19 19:10; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Natural Gas Rises in Volatile Trading -- Market Talk

2026-03-19 19:06; UTC

Svarbiausios naujienos

Brent Crude Prices Are Surging. Why Europe Is Facing an Energy Shock and the U.S. Isn't. -- Barrons.com

2026-03-19 18:08; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Silver Extends Slide to Seven Straight Sessions -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

33.31% į viršų

12 mėnesių prognozė

Vidutinis 95.54 USD  33.31%

Aukščiausias 110 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

11

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

155 / 350 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat